766 Background: Patients with metastatic colorectal cancer (CRC) usually receive multiple lines of treatment. Using a present day standard 1st line chemotherapy combination a progression free survival in the range of 8-12 months can be obtained. With consecutive treatment lines the median survival has now exceeded the 2-year landmark. In case of disease progression after two or more lines of treatment, the survival is about 4-6 months with best supportive care alone. However, some patients are still able and willing to receive further therapy. In the present retrospective analysis the efficacy of a weekly intravenous high-dose infusion of 5-Fluorouracil and folinic acid in heavily pretreated patients with metastatic CRC beyond the standard chemotherapy lines was evaluated. Methods: The Klinikum Wels-Grieskirchen collects data on all CRC patients since July 2006 in a clinical tumor registry. In this retrospective analysis pretreated CRC patients that were treated with the Ardalan-regimen (500mg/m2 folinic acid as 1 hour infusion followed by 2.600mg/m25-Fluorouracil as 24-hour infusion) have been evaluated. Results: A total of 23 evaluable patients with a median age of 66 years received the Ardalan-regimen as 2nd (4.4%), 3rd (13%), 4th (13%), 5th (52.2%), 6th (4.4%) or 7th (13%) line treatment. The median number of cycles received was 9 (range 2-18) and the Ardalan-regimen was started within 13-56 months (median 26 months) after the diagnosis of metastatic disease. Fourteen (60.9%) and nine (39.1%) out of these patients were women and men, respectively. 60.9% (14 patients) had a tumor located in the colon and 39.1% had rectal cancer. 17.4% of patients had stable disease and 65.2% of patients had progressive disease after 3 months of therapy. In 4 patients response according to RECIST criteria was not evaluable. Median overall survival since the start of the Ardalan-regimen was 6.7 months. Conclusions: Patients with advanced metastatic CRC can be candidates for multiple lines of therapy. In previously heavily pretreated patients, the Ardalan-regimen is able to control the disease in a limited proportion of patients.
Retrospective analysis of TAS-102 for metastatic colorectal cancer
